Business Description
3SBio Inc
NAICS : 325412
SIC : 2834
ISIN : KYG8875G1029
Share Class Description:
FRA:83B: Shs Unitary 144A/Reg SCompare
Compare
Traded in other countries / regions
01530.Hong KongTRSBF.USA83B.Germany IPO Date
2015-06-11Description
3SBio Inc is a biotechnology company. As a pioneer in the Chinese biotechnology industry, the Group has extensive expertise in researching, developing, manufacturing, and marketing biopharmaceuticals. The core products of the Group include several biopharmaceutical drugs, TPIAO recombinant human erythropoietin rhEPO products EPIAO and SEPO, Yisaipu, Cipterbin, and a small molecule drug, Mandi. Except for minoxidil, an over-the-counter drug, the others are all older-generation biologics.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.24 | |||||
Equity-to-Asset | 0.59 | |||||
Debt-to-Equity | 0.35 | |||||
Debt-to-EBITDA | 1.92 | |||||
Interest Coverage | 11.58 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 2.65 | |||||
Beneish M-Score | -2.35 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 13.3 | |||||
3-Year EBITDA Growth Rate | 22.7 | |||||
3-Year EPS without NRI Growth Rate | 19.8 | |||||
3-Year FCF Growth Rate | 58.2 | |||||
3-Year Book Growth Rate | 8.7 | |||||
Future 3-5Y Total Revenue Growth Rate | 8.5 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 55.07 | |||||
9-Day RSI | 52.21 | |||||
14-Day RSI | 50.97 | |||||
6-1 Month Momentum % | -12.58 | |||||
12-1 Month Momentum % | -18.24 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.47 | |||||
Quick Ratio | 2.26 | |||||
Cash Ratio | 1.61 | |||||
Days Inventory | 232.63 | |||||
Days Sales Outstanding | 54.69 | |||||
Days Payable | 76.74 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 1.68 | |||||
Dividend Payout Ratio | 0.13 | |||||
Forward Dividend Yield % | 4.26 | |||||
5-Year Yield-on-Cost % | 1.69 | |||||
3-Year Average Share Buyback Ratio | 1.9 | |||||
Shareholder Yield % | -2.27 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 84.98 | |||||
Operating Margin % | 31.45 | |||||
Net Margin % | 19.82 | |||||
FCF Margin % | 17.64 | |||||
ROE % | 11.41 | |||||
ROA % | 6.71 | |||||
ROIC % | 12.36 | |||||
ROC (Joel Greenblatt) % | 40 | |||||
ROCE % | 10.94 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 9.48 | |||||
PE Ratio without NRI | 8.19 | |||||
Shiller PE Ratio | 12.72 | |||||
Price-to-Owner-Earnings | 11.75 | |||||
PEG Ratio | 0.77 | |||||
PS Ratio | 1.84 | |||||
PB Ratio | 1.01 | |||||
Price-to-Tangible-Book | 1.68 | |||||
Price-to-Free-Cash-Flow | 10.44 | |||||
Price-to-Operating-Cash-Flow | 6.9 | |||||
EV-to-EBIT | 5.93 | |||||
EV-to-Forward-EBIT | 5.7 | |||||
EV-to-EBITDA | 5.14 | |||||
EV-to-Forward-EBITDA | 4.88 | |||||
EV-to-Revenue | 1.66 | |||||
EV-to-Forward-Revenue | 1.5 | |||||
EV-to-FCF | 9.42 | |||||
Price-to-Projected-FCF | 0.58 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.77 | |||||
Price-to-Graham-Number | 0.78 | |||||
Earnings Yield (Greenblatt) % | 16.86 | |||||
FCF Yield % | 9.76 | |||||
Forward Rate of Return (Yacktman) % | 16.85 |